Response assessment using [68 Ga]Ga-PSMA ligand PET in patients undergoing systemic therapy for metastatic castration-resistant prostate cancer

Bernhard Grubmüller, Sazan Rasul, Pascal Baltzer, Harun Fajkovic, David D'Andrea, Florian Berndl, Agnes Maj-Hes, Karl Hermann Grubmüller, Markus Mitterhauser, Wolfgang Wadsak, Sarah Pfaff, Shahrokh F Shariat, Marcus Hacker, Gero Kramer, Markus Hartenbach

Research output: Journal article (peer-reviewed)Journal article

31 Citations (Scopus)

Abstract

BACKGROUND: To assess which parameters of [68 Ga]Ga-PSMA-11 positron emission tomography (PSMA-PET) predict response to systemic therapies in metastatic (m) castration-resistant prostate cancer (CRPC). In addition, to investigate which of these factors are associated with overall survival (OS).

METHODS: We retrospectively assessed the following PSMA-PET parameters in 43 patients before and after systemic therapies for mCRPC: PSMA total tumor volume (TTV), mean standardized uptake value (SUVmean), SUVmax, and SUVpeak. prostate-specific antigen (PSA) levels and PSMA-PET/CT(magnetic resonance imaging [MRI]) imaging were both performed within 8 weeks before and 6 weeks after systemic therapy. PSMA-PET and CT (MRI) images were reviewed according to the modified PET Response Criteria in Solid Tumors (PERCIST) and Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Results were compared to PSA response. Univariable survival analyses were performed.

RESULTS: Overall, 43 patients undergoing 67 systemic therapies were included (9 patients radium-223, 12 cabazitaxel, 22 docetaxel, 6 abiraterone, and 18 enzalutamide). Median serum PSA level before any therapy was 11.3 ng/mL (interquartile range [IQR] = 3.3, 30.1). Delta (d) PSA after systemic therapies was -41%, dTTV 10.5%, dSUVmean -7.5%, dSUVmax -13.3%, dSUVpeak -12%, and dRECIST -13.3%. Overall, 31 patients had dPSA response (46.3%), 12 stable disease (17.9%), and 24 progressive disease (35.8%). All observed PET parameters, as well as the RECIST evaluation, were significantly associated with PSA response (dTTV P = .003, dSUVmean P = .003, dSUVmax P = .011, dSUVpeak P < 0001, dRECIST P = .012), while RECIST assessment was applicable in 37 out of 67 patients (55.2%). Within a median follow-up of 33 months (IQR = 26, 38), 10 patients (23.3%) died of PC. On univariable survival analyses, neither the investigated PET parameters nor PSA level or RECIST criteria were associated with OS.

CONCLUSION: PSMA-PET provides reliable parameters for prediction of response to systemic therapies for mCRPC. These parameters, if confirmed, could enhance RECIST criteria, specifically concerning its limitations for sclerotic bone lesions.

Original languageEnglish
Pages (from-to)74-82
Number of pages9
JournalProstate
Volume80
Issue number1
DOIs
Publication statusPublished - 1 Jan 2020

Keywords

  • Aged
  • Edetic Acid/analogs & derivatives
  • Gallium Isotopes
  • Gallium Radioisotopes
  • Humans
  • Male
  • Neoplasm Metastasis
  • Oligopeptides
  • Positron-Emission Tomography/methods
  • Prostatic Neoplasms, Castration-Resistant/diagnostic imaging
  • Radiopharmaceuticals
  • Retrospective Studies
  • PSMA ligand
  • hybrid imaging
  • PET/MRI
  • PET/CT
  • metastatic prostate cancer

ASJC Scopus subject areas

  • Urology
  • Oncology

Fingerprint

Dive into the research topics of 'Response assessment using [68 Ga]Ga-PSMA ligand PET in patients undergoing systemic therapy for metastatic castration-resistant prostate cancer'. Together they form a unique fingerprint.

Cite this